The ROE as of December 2025 (TTM) for Celyad Oncology S.A. (CLYYF) is 67.42%

According to Celyad Oncology S.A.’s latest financial reports and current stock price. The company's current ROE is 67.42%. This represents a change of -959.95% compared to the average of -7.84% of the last 4 quarters.

Celyad Oncology S.A. (CLYYF) Historical ROE (quarterly & annually)

How has CLYYF ROE performed in the past?

The mean historical ROE of Celyad Oncology S.A. over the last ten years is -146.32%. The current 67.42% ROE has changed -146.07% with respect to the historical average. Over the past ten years (40 quarters), CLYYF's ROE was at its highest in in the June 2013 quarter at 572.93%. The ROE was at its lowest in in the June 2023 quarter at -367.03%.

Celyad Oncology S.A. (CLYYF) ROE by Quarter and Year

Discovering the peaks and valleys of Celyad Oncology S.A. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Celyad Oncology S.A. (CLYYF) Average ROE

How has CLYYF ROE performed in the past?

The current ROE of Celyad Oncology S.A. (CLYYF) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Celyad Oncology S.A. (CLYYF) ROE vs. Peers

How is CLYYF’s ROE compared to its peers?

Celyad Oncology S.A.’s ROE is less than ERYTECH Pharma S.A. (0%), greater than Molecular Partners AG (-95.68%), greater than XORTX Therapeutics Inc. (-50.31%), greater than Nutriband Inc. (-73.46%), greater than YS Biopharma Co., Ltd. (-131.40%), greater than Sonnet BioTherapeutics Holdings, Inc. (-18.43%), greater than ZyVersa Therapeutics, Inc. (-4648.06%), less than Allarity Therapeutics, Inc. (677.15%), greater than Kiromic BioPharma, Inc. (-112.05%), less than Claritas Pharmaceuticals, Inc. (231.14%), greater than Intellipharmaceutics International Inc. (-436.27%), less than Metacrine, Inc. (27.35%), greater than ForU Holdings, Inc. (-83.52%), less than ChitogenX Inc. (528.41%), less than Aditxt, Inc. (13.28%), greater than Palisade Bio, Inc. (-550.61%), greater than Plus Therapeutics, Inc. (-240.71%), less than Revelation Biosciences, Inc. (335.91%), greater than Quoin Pharmaceuticals, Ltd. (-194.47%), greater than Virax Biolabs Group Limited (-210.51%), greater than Blue Water Vaccines, Inc. (-84.53%), greater than Hillstream BioPharma, Inc. (-839.59%), greater than Kiora Pharmaceuticals, Inc. (-1397.15%), greater than null (-47.17%),

Build a custom stock screener for Celyad Oncology S.A. (CLYYF) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Celyad Oncology S.A. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Celyad Oncology S.A. (CLYYF) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Celyad Oncology S.A. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.